Previous 10 | Next 10 |
2024-03-08 10:21:57 ET More on Teva Pharmaceutical Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position A Review Of Teva's Prospects UroGen falls as Te...
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health Canada NewsWire Organon Canada launches 'HER Professional Journey' to support female employees to navigate their career paths, ...
2024-02-26 12:22:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some stocks glitter more prominently than others in the vast investment pool. However, amidst the popularity of high-profile names, a line of overlooked stocks exists, steadily leading to a mar...
2024-02-23 22:44:00 ET Summary A quarter has passed since I initiated a "Buy" rating on Organon. In this time, the stock has gained around 63% - that's 7x more than S&P 500 index. Despite established brand segment challenges, Organon's proactive measures to sustain growth thro...
2024-02-22 11:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary. HADLIMA is an FDA-approved biosimilar to HUM...
2024-02-16 11:45:57 ET Summary Organon's Q4 earnings report led to a surge in share price, reaching a 6-month high of $18. FY revenues were $6.2bn, and adjusted EBITDA $1.9bn. The company's focus on developing new revenue streams in Women's Health and Biosimilars is starting to sh...
2024-02-15 12:06:05 ET Organon & Co. (OGN) Q4 2023 Earnings Conference Call February 15, 2024, 08:30 AM ET Company Participants Jennifer Halchak - Vice President of Investor Relations Kevin Ali - CEO & Director Matthew Walsh - Executive VP & CFO ...
2024-02-15 11:33:25 ET More on Organon Organon & Co. 2023 Q4 - Results - Earnings Call Presentation Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 Organon beats top-li...
2024-02-15 07:50:53 ET More on Organon Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Orga...
News, Short Squeeze, Breakout and More Instantly...
2024-08-03 07:45:00 ET As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump’s assertion that Harris would be an easier opponent than Joe Biden, recent developments sugge...
2024-08-02 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...